Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.
This settlement is closed!
Please see what other class action settlements you might qualify to claim cash from in our Open Settlements directory!
Update:
- The court granted this settlement final approval on March 15, 2023.
- Let Top Class Actions know when you receive a check in the comments section below or on our Settlements & Payouts Facebook group.
Johnson & Johnson and Janssen Biotech agreed to a $25 million class action lawsuit settlement to resolve claims they suppressed Remicade (infliximab) generic competitors.
The settlement benefits individuals and entities who indirectly purchased, paid for or provided reimbursement for some or all of the purchase price of Remicade (infliximab) between April 5, 2016, and Feb. 28, 2022.
Remicade (infliximab) is a biologic drug used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis, according to Rheumatology.org. The drug treats these conditions by stopping the body’s inflammation process.
In 2018, a consolidated class action lawsuit was filed against Johnson & Johnson and Janssen Biotech accusing the companies of suppressing competitors to Remicade ino order to secure a monopoly on the infliximab market.
Plaintiffs say the two biomedical companies “worked to suppress competition and raise prices to purchases of [Remicade] by imposing a web of exclusionary contracts on both health insurers and healthcare providers” and “engaged in other anticompetitive conduct.” As a result of these actions, competitor products were allegedly barred from the market and the plaintiffs and other consumers were forced to pay more for Remicade than they would have in a competitive market.
The antitrust class action lawsuit contends that Johnson & Johnson and Janssen Biotech violated the federal Sherman Antitrust Act and Clayton Act, as well as state laws.
After four years of litigation, the defendants haven’t admitted any wrongdoing but agreed to pay $25 million to resolve these allegations.
Under the terms of the Remicade settlement, class members can collect a share of the settlement fund.
Class members who paid more for Remicade during the class period will receive a larger share of the settlement fund. Class members may need to provide detailed purchase information to validate their claims.
Exact payment amounts will vary but will be at least $25. Class members whose share of the settlement fund would be less than $25 will not receive a settlement payment.
If funds remain after the initial distribution, a second round of checks may be sent to class members. This second distribution will only occur if each class member would receive at least $10. If remaining funds do not warrant a second distribution, the money will be donated to the Crohn’s & Colitis Foundation or another non-profit approved by the court.
The deadline for exclusion and objection is Nov. 30, 2022.
The final approval hearing for the Remicade settlement is scheduled for Feb. 27, 2023.
In order to receive benefits from the Remicade settlement, class members must submit a valid claim form by Nov. 30, 2022.
Who’s Eligible
The settlement benefits individuals and entities who indirectly purchased, paid for or provided reimbursement for some or all of the purchase price of Remicade (infliximab) between April 5, 2016, and Feb. 28, 2022.
Potential Award
Varies
Proof of Purchase
You will be asked to provide information or data proving that you are a member of the Settlement Class. You also may be asked to provide data showing your eligible purchases.
Claim Form
NOTE: If you do not qualify for this settlement do NOT file a claim.
Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.
Claim Form Deadline
11/30/2022
Case Name
Remicade Antitrust Litigation, Case No. 2:17-cv-04326-KSM, in the District Court for the Eastern District of Pennsylvania
Final Hearing
02/27/2023
Settlement Website
Claims Administrator
Remicade Antitrust Litigation
c/o Gilardi & Co
Settlement Administrator
P.O. Box 6175
Novato, CA 94947-6175
info@RemicadeSettlement.com
888-859-1912
Class Counsel
Alexandra S Bernay
ROBBINS GELLER RUDMAN & DOWD LLP
Defense Counsel
William F Cavanaugh
PATTERSON BELKNAP WEBB & TYLER LLP
Read About More Class Action Lawsuits & Class Action Settlements:
- False advertising lawsuits, recalls plague supplements and OTC medications
- Walgreens responsible for opioid epidemic in Bay Area, judge rules
- Dilantin long term side effects may include brain damage
- Cerebellar atrophy linked to long-term use of Dilantin
ATTORNEY ADVERTISING
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2024 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.
12 thoughts onRemicade (infliximab) antitrust $25M class action settlement
Why is this taking so long? No updates or anything.
Isn’t it time for this one to pay? Distribution of funds were approved in March.
Please add me
I am on remicade by injection
Please add my name
Please add me
How to get a claim number. I’ve been in Remicade for years for Ulcerative Colitis and have to pay deductible every 8 weeks I go. Please add me.
Add My Name
Thank You
I have been on Remicade for years
Add me please
Add me please
Add me
Add me